Detail akcie DexCom online

Business Summary: DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
Financial Summary: BRIEF: For the three months ended 31 March 2026, DexCom Inc revenues increased 15% to $1.19B. Net income increased 89% to $199.5M. Revenues reflect Distributor segment increase of 15% to $1.01B, Direct segment increase of 16% to $181.6M, United States segment increase of 11% to $832.3M, Outside of United states segment increase of 26% to $359.6M. Net income benefited from Interest Expenses decrease of 34% to $3.1M (expense).